Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $925.00 price target on the stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? [Yahoo! Finance]
UPDATE 1-Regeneron misses profit estimates on weaker Eylea and Dupixent sales [Yahoo! Finance]
Regeneron Reports First Quarter 2024 Financial and Operating Results [Yahoo! Finance]